Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a research report released on Saturday morning.

Several other equities research analysts have also commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday. Royal Bank Of Canada lowered their price target on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating on the stock in a report on Thursday. Finally, Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $826.59.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $701.42 on Friday. The firm has a market capitalization of $74.15 billion, a PE ratio of 17.09, a price-to-earnings-growth ratio of 1.61 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 3.39. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $821.11. The company’s fifty day moving average price is $756.81 and its 200-day moving average price is $736.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the company earned $8.22 earnings per share. The firm’s revenue was up 19.0% on a year-over-year basis. On average, equities research analysts predict that Regeneron Pharmaceuticals will post 36.05 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.16%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 3,774 shares of company stock worth $2,942,738. Company insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of REGN. WPG Advisers LLC raised its position in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the period. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $26,000. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $27,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $29,000. Finally, Board of the Pension Protection Fund acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a “sector perform” stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today’s weaker price action. Regeneron drops despite Q1 beat

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.